SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001829126-23-001405
Filing Date
2023-02-09
Accepted
2023-02-09 16:51:26
Documents
12
Period of Report
2023-02-08
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K titanpharma_8k.htm   iXBRL 8-K 34407
  Complete submission text file 0001829126-23-001405.txt   208333

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE ttnp-20230208.xsd EX-101.SCH 3233
3 XBRL LABEL FILE ttnp-20230208_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE ttnp-20230208_pre.xml EX-101.PRE 22363
6 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_8k_htm.xml XML 3626
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 23607030
SIC: 2836 Biological Products, (No Diagnostic Substances)